Non-anesthetic effects of ketamine, a review article
Jabril Eldufani, Alireza Nekoui, Gilbert Blaise

DOI: 10.1016/j.amjmed.2018.04.029

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Highlights

- Ketamine has a variety of pharmacological effects including sedation, analgesia, bronchodilation, and nervous system stimulation.
- It is used as an active adjuvant that prolongs the duration of analgesic effect of painkillers in pain management.
- Ketamine is utilized in clinical practice to manage major resistant depression, enhance memory function in Alzheimer’s patients, and reduce the brain damage after stroke.
- Ketamine is clinically used for managing cognitive function, and immune system disorders.
Title:

Non-anesthetic effects of ketamine, a review article Authors:

Jabril Eldufani, MD, MSc\textsuperscript{1}, Alireza Nekoui, MD, MSc\textsuperscript{1}, Gilbert Blaise, MD, PhD\textsuperscript{1,2}

\textsuperscript{1}Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
\textsuperscript{2}Department of Anesthesiology and Pain Management, Centre Hospitalier de l’université de Montréal (CHUM), Montreal, Quebec, Canada

Jabril Eldufani, MD, MSc
529, rue Jarry est, Bureau 400 Montréal QC H2P 1V4 Canada.
\texttt{Jabril.Eldufani@umontreal.ca}

Alireza Nekoui, MD, MSc
529, rue Jarry est, Bureau 400 Montréal QC H2P 1V4 Canada.
\texttt{alinekoui@yahoo.com}

Gilbert Blaise, MD, PhD
529, rue Jarry est, Bureau 400 Montreal QC H2P 1V4 Canada.
\texttt{blaisegil@videotron.ca}

Corresponding author:

Jabril Eldufani MD, MSc,
529, rue Jarry est, Bureau 400 Montréal QC H2P 1V4 Canada.
Telephone: +1 438-386-7882
E-mail: \texttt{Jabril.Eldufani@umontreal.ca}
Declarations of interest: none

Conflict of interest for all authors: none

Funding: none

Author roles: All authors had a role in writing the manuscript

Running title: Non-anesthetic effects of ketamine

Article Type: Review article

Key Words: ketamine, chronic pain, N-methyl-d-aspartate receptor antagonist, depression, brain injury, immune system.
Abstract

Ketamine is considered a dissociative anesthetic medication, and it is a commonly administered by a parenteral route. It works mainly by blocking the N-methyl-D-aspartate (NMDA) receptor. It inhibits the voltage-gated Na_ and K_ channels and serotonin and dopamine re-uptake; also, it affects specific receptors, such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and aminobutyric acid A receptors. Ketamine appears to have particular mechanisms that are potentially involved during analgesic induction, including enhancing of descending inhibition and anti-inflammatory effects. More recently, it has been shown that ketamine has potential in clinical practice for the management of chronic pain, cognitive function, depression, acute brain injury and disorders of the immune system.
Introduction

Since 1970, ketamine has been clinically used as an anesthetic medication (1). It is thought to modulate N-methyl-D-aspartate (NMDA), \( \alpha \)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, and aminobutyric acid-A receptors (1, 2). Its ability to inhibit the voltage-gated Na\(_\text{+}\) and K\(_\text{+}\) channels and serotonin and dopamine reuptake might be useful in some clinical conditions, such as managing chronic pain, depression, acute brain injury, etc. (1,3). Ketamine has been used in clinical practice in different medical specialties (4, 5). It produces a wide variety of pharmacological effects, including sedation, analgesia, bronchodilation, and sympathetic nervous system (SNS) stimulation (4, 6, 7). Anesthesiologists and pain specialists have begun to use ketamine, in sub-anesthetic doses, for the long-term treatment of chronic refractory pain, particularly neuropathic pains, such as complex regional pain syndrome, post-herpetic neuralgia and diabetic neuropathic pain (4, 8, 9).

The pharmacological and anesthetic properties of ketamine have been identified since 1965 (10). Ketamine is known as a dissociative anesthetic agent that produces strong analgesia and amnesia (10, 11). In addition, it elicits a variety of side effects, such as the induction of psychedelic conditions leading to hallucinations and excitation symptoms (12-13).

In this review, we will discuss the relevant literature on the potential benefits and risks of ketamine use in pathological conditions, including managing chronic pain, cognitive function, depression, acute brain injury, and immune system disorders.
Pharmacology

Ketamine can rapidly pass the blood-brain barrier and, therefore, has a quick onset of analgesic effect (14, 15). Ketamine potentially produces an analgesic effect at several sites of the nervous system, both centrally and peripherally (16, 17, 18). New research shows that ketamine has inhibitory effects on voltage-gated Na and K channels, serotonin receptors and it inhibits dopamine reuptake (19, 20, 21). The mechanism of action of ketamine is thought to involve an interaction between N-methyl-D-aspartate receptors, the nitric oxide pathway, and opioid receptors (22, 23).

Chronic pain

Ketamine is administered to treat various diseases that cause chronic refractory pain, particularly those that have a neuropathic component (24). It has recently been reported that a low intravenous dose of ketamine produces potent analgesia in neuropathic pain conditions, presumably by inhibition of the N-methyl-D-aspartate receptor (24). However, it appears that particular mechanisms are potentially involved, including enhancing of the descending inhibition and anti-inflammatory effects (25). In chronic pain conditions, prolonged nociceptive stimulation leads to activation and upregulation of the N-methyl-D-aspartate receptors at the dorsal horn synapses resulting in enhancing and amplifying pain signals to the brain (26). This phenomenon would be a significant factor in the process of perseverance and eventual chronification of pain (27, 28).

More recently, research has shown that N-methyl-D-aspartate receptor antagonists,
such as ketamine, can halt the excessive barrage of nociceptive input to the brain and, therefore, are possible alternatives to existing therapies of chronic pain syndromes (27, 29). Also, there are other effects of ketamine that might contribute to its analgesic behavior by enhancing the descending inhibition pathway, especially in patients with chronic neuropathic pain (29). Indeed, ketamine could prevent the occurrence of chronic pain conditions, such as that experienced in the postsurgical period after lower limb amputation (28). In order to achieve adequate management of chronic pain, it is preferred to use a multimodal approach to different medications (27, 28).

Several clinical studies have reported that using ketamine with morphine in the treatment of chronic cancer pain has reduced morphine consumption with less pain and fewer adverse effects (27). Ketamine improves the efficacy of opioid treatment in chronic cancer pain during long-term management (27). This is because ketamine’s ability to reduce neuropathic pain is superior to that of opioids, but it can additively and synergistically interact with opioids, probably through the descending inhibitory pathway. Some experimental studies in mice lacking μ-opioid receptors have suggested a crucial role of the μ-opioid receptor in ketamine-induced acute analgesia (27). However, the inhibitory pathway of presynaptic spinal dorsal neurons would also achieve relieving acute pain (29, 30). The activation of N-methyl-D-aspartate receptor at these presynaptic areas could lead to the release of excitatory substances, including glutamate and substance P (27, 30).

**Cognitive function**

Analysis of cognitive and memory functions during short-term ketamine infusion
has demonstrated impairment of working memory and reduction in the encoding of information into episodic memory (27). In contrast to other amnestic medications, ketamine impairs semantic memory in some patients (27). After the termination of short duration and single ketamine infusions, memory function reverts to a healthy state, which possibly indicates ketamine-induced memory loss is self-resolving (27). However, the effects on memory function of the long-term use of low-dose ketamine for the treatment of chronic pain are poorly reported and, consequently, unknown (27). Nevertheless, a recent clinical study that examined the safety of high-dose, long-term ketamine in complex regional pain syndrome (CRPS) patients who received anesthetic doses over 5 days demonstrated no severe cognitive defects (27).

The use of ketamine for neuroprotection (either intraoperatively or in the intensive care unit setting with adequate neurocognitive or neuroradiological follow-up), in clinical studies, could support the hypothesis that ketamine may protect cognitive functions (31). One research group has been particularly interested in the potential of ketamine’s neuroprotection mechanism to alleviate postoperative cognitive dysfunction (POCD) in non-head trauma patients (31). Several clinical investigations have proven that a single dose of ketamine (0.5 mg/Kg) at induction of anesthesia phase maybe attenuated postoperative cognitive dysfunction in patients undergoing cardiac surgery (31). Additionally, they have demonstrated ketamine has a potential induction phase that reduces the incidence of postoperative delirium from 31% to 3% (31). Thus, these beneficial effects of ketamine are thought to contribute to the mitigation of the postoperative systemic inflammatory response (31).

One study, in which patients reached a Ramsay Score 4–5 depth of anesthesia and
had ketamine levels of 250–300 µg/dL for at least 4.5 days (i.e., in a medically-induced coma), reported that deep ketamine therapy was effective for relief of chronic pain and without harmful cognitive effects (32). Studies have suggested that ketamine and other antidepressants mediate glutamate and neurotrophic receptors (32). This leads to a stimulation of the mammalian target of rapamycin (mTOR) pathway in the prefrontal cortex (PFC), thereby resulting in transient activation of the downstream effectors, such as 4E-binding protein 1 and protein S6 kinase (32).

Significantly, the activation of mammalian target of rapamycin after ketamine administration would potentially indicate an association between significant deficits in synaptic proteins and dysregulation of the mammalian target of rapamycin pathway in patients with the major depressive disorder (MDD) (33, 34). Recently, some studies have focused on neuroinflammation and oxidative stress mechanisms in major depression (33, 35). For example, an agonist of peroxisome proliferator-activated receptor-α (PPAR-α) was reported to inhibit neuroinflammation and oxidative stress, and it possessed the antidepressant-like effects of ketamine by preventing the neuroinflammation of many proteins that are involved in inflammation-related genes, including chemokines and interferon-gamma-induced genes (33, 36, 37).

**Dementia and Alzheimer’s disease**

Ketamine is known as a noncompetitive N-methyl-D-aspartate receptor antagonist (16, 38, 39). Therefore, administration of ketamine and other N-methyl-D-aspartate receptor antagonists, such as memantine, is used to improve the symptoms Alzheimer’s disease (AD) (40). Some studies have revealed (the excitotoxic hypothesis) that there are
glutamatergic hyperactivity receptors in Alzheimer’s disease. Neuronal and astroglial glutamate transporter dysfunction in Alzheimer’s disease may be lead to excess glutamate in the synaptic cleft and excitotoxic neuronal damage (40, 41). In addition, in the hippocampus and the striatum, cholinergic neurons can control the liberation of acetylcholine (42). Thus, in the prefrontal cortex, these cholinergic neurons would be mediated by nicotinic and muscarinic receptors (42, 43). Ketamine plays a vital role in the occurrence of psychic phenomena by a direct inhibiting effect on these receptors (42, 43).

Additionally, ketamine may facilitate acetylcholine liberation in the hippocampus because the release of dopamine has increased (16). Clinically, sufficient concentrations of ketamine could inhibit acetylcholine liberation by N-methyl-D-aspartate receptors (16) and inhibit nicotinic receptors (44). In addition, it has antagonist activity on muscarinic receptors (45). The N-methyl-D-aspartate receptor, blocked by ketamine for concentrations between 2 and 50 µm intramuscular (IM), is responsible for ketamine’s most essential pharmacological properties (45). Glutamate is the most prevalent amino acid in the central nervous system (CNS), involving glutamatergic synapses (45). N-methyl-D-aspartate receptors are present on nearly all the neural cells of the central nervous system, particularly in the structures implicated in nociception, such as primary afferents or spinal dorsal horn (46). When glutamate is released in the synaptic cleft, there is an activation of the postsynaptic ionotropic receptors, which leads to the opening of ion channels, and is then responsible for a membrane depolarization (46).

Oxidative stress and protein damage are the processes related to the pathogenesis of Alzheimer’s disease (47). The hippocampus, which is mainly affected by Alzheimer’s
disease, is a significant structure for memory function of humans and spatial memory of rodents (47). Several studies have reported that a single sub-anesthetic dose of ketamine increases lipid peroxidation and protein damage in the hippocampus (47). It was shown that the hippocampus is involved in three stages of the memory mechanism: acquisition, consolidation, and retrieval (47). Therefore, considering ketamine-induced protein damage in the hippocampus, as well as its antagonism effect of N-methyl-D-aspartate receptors, a study in mice was conducted to assess the impact of a sub-anesthetic dose of ketamine on those three stages (48). The results showed that pre-training administration of a sub-anesthetic dose of ketamine deteriorates learning and pre-probe administration of ketamine impaired performance in the probe trial (47, 48). However, post-training administration of ketamine did not effect on the animals’ performance. The study shows that sub-anesthetic ketamine could affect memory acquisition and retrieval, but does not reduce memory consolidation (47, 48).

## Depression

Antidepressant actions in animal models have been demonstrated with ketamine, as have rapid antidepressant effects in human studies (49, 50). Ketamine is a high-affinity N-methyl-D-aspartate receptor antagonist, which also binds to opioid μ and sigma receptor (51). Ketamine was reported to regulate dopamine transmission and reuptake (52, 53). Treatment-resistant depression affects over 1% of individuals in the United States, and nearly 30% of all depressed patients (54). Ketamine has active and rapid antidepressant properties, so it is suggested for treating resistant depression (TRD) (54). Ketamine may be considered as a novel pharmacological medication for managing both...
major depressive disorder and treatment-resistant depression (TRD) patients (55). Ketamine’s action is rapid in contrast to the delayed response of the currently available antidepressant agents, which require several weeks to produce an effect (55, 56).

Several studies have provided highly valuable insight into the neural systems that are involved in the antidepressant effects of ketamine (57). Indeed, the long-term beneficial actions of ketamine on depressive symptoms are noticeable; however, there is no current research available for addressing the long-term effect of a single injection of ketamine on brain circuitry in major depressive disorder (57). To understand the vital role of the brain reward system in the pathophysiology of the major depressive disorder, we need to produce genetic evidence that suggests Brain-Derived Neurotrophic Factor (BDNF) plays a crucial role in this process (57). However, the downstream signaling pathways, which mediate the actions of this neurotrophin, have been identified (57). A significant amount of experimental data demonstrates that ketamine can interact with the majority of cellular signaling pathways that are involved in major depressive disorder (57, 58). The antidepressant behavioral effects of ketamine were inhibited in conditional Brain-Derived Neurotrophic Factor deletion mutant mice, as well as after the infusion of a function-blocking anti-Behavioral Effects of Antidepressant Factors antibody into the prefrontal cortex (51, 58, 59).

Ketamine has demonstrated antidepressant effects in patients with the major depressive disorder, and its results have been reported in several studies for treatment-resistant depression (60). Preclinical studies have shown ketamine has antidepressant effects in some animal models of depression by expressing serine/threonine protein kinase (60). This is called the mammalian target of rapamycin, which modulates cell
growth, proliferation, motility, survival, and protein synthesis (60). These observations have provided a mechanistic explanation of how decreased levels of Brain-Derived Neurotrophic Factor and downstream mechanistic target of rapamycin complex 1 signaling, associated with depressive symptoms could be reversed via rapid-acting antidepressants, such as ketamine (Figure 1) (57).

Pharmacologically, several studies that determine the concentration and administration speed-dependent effects of ketamine in depression are needed (61). Recently, one study suggested that the results of ketamine on mood are dose-dependent (61). The investigators have recently compared the effects of 0.1–0.4 mg/kg of ketamine in patients with the major depressive disorder and found vast improvements were achieved at the highest dose level (62). In addition, recent data suggest the effectiveness of ketamine in reducing suicidality and in alleviating posttraumatic stress disorder (PTSD) symptoms might also extend in parallel with its antidepressant effects (62).

**Acute brain injury**

The occurrence of traumatic brain injury is high; incidence is increased in developing countries and exceeds that of the developed world (63). Therapeutic strategy for reducing traumatic brain injury or stroke after ischemia or trauma is well defined (63). The treatment is aimed at alleviating secondary damage, which occurs within hours to days after an acute brain insult (63). Neuroscientists and clinicians have struggled to identify the cause and consequences of this secondary damage (64). Successful treatment of stroke and diffuse brain injury lies in understanding the complexity of the processes involved in perpetuating subsequent cell death, which requires a compound capable of
mitigating each of these processes (64).

There was some concern regarding the use of ketamine in the neurosurgical and acute brain injury populations due to adverse effects, as it may increase intracranial pressure (64). More recently, reevaluation of the medication has shown this to be incorrect, particularly in patients on mechanical ventilation (64, 65). In 1996, ketamine was shown to reduce cell injury in axotomy of peripheral neurons and motoneurons in cell cultures (66). This resulted in improving neuronal survival, by using experimental animal models of stroke and brain trauma to reduce neuronal discharge and damage as seen in status epilepticus (67, 68, 69). Many studies have shown that using ketamine leads to minimized focal ischemia size and decreased volume of hemorrhagic necrosis in experimental head injury models (66, 67, 70). These preclinical investigations have determined that ketamine provides histopathologic and physiological neuroprotection across extended arrangements of acute neuroinjury models (70).

Additionally, research has shown that ketamine has a potent extrasynaptic antagonistic effect, extensively inhibiting stimulation of the selectively neurotoxic NR2B-containing N-methyl-D-aspartate receptors (34, 71). Ketamine has antiglutamatergic impacts that might have a role in the management of delayed cerebral ischemia following subarachnoid hemorrhage (SAH) and cerebral vasospasm (72, 73). Therefore, ketamine may play a profound role in the reduction of glutamate-induced cell death.
**Immune system**

Ketamine reduces tissue necrosis factor α (TNF-α), interleukins (IL) and nitric oxide (NO) production, all of which play vital roles during the inflammatory process, and the inhibition of these activities could affect macrophage-mediated immunity (74). The potential mechanism of ketamine-induced immunosuppression was studied to evaluate effects in macrophages, tissue necrosis factor α, interleukins-1β, and interleukins-6 messenger ribonucleic acid (mRNA) syntheses, and it was found that ketamine inhibited messenger ribonucleic acid syntheses by lipopolysaccharide (LPS)-activated macrophages (74). Ketamine has recently been used as an anti-inflammatory drug, which emphasizes the significance of research on its interactions with the immune system (74). Indeed, major surgery or sepsis leads to the release of proinflammatory mediators, including large amounts of cytokines, which can lead to undesirable effects, such as low blood pressure and multiple organ failures (30, 74).

Moreover, ketamine has a double effect that connects both the analgesic and neuroprotective actions of its anti-inflammatory effects; ketamine regulates the inhibition of tumor necrosis factor α, interleukin 6 and proinflammatory cytokine activities that would occur in both peripheral immune cells and glial cells in the central nervous system (37, 75). The primary protective inflammatory mechanism in the central nervous system in defense of brain injury is often rapidly deregulated in a cerebrovascular accident (74). For example, in stroke, as a result of excessive microglial activation with release of tissue necrosis factor α that leads to stimulation of the extrinsic apoptotic pathway, as well as interleukins-1β, interleukins-8, and interleukins-6 (74, 76). This, in turn, might lead to
enhance blood-brain barrier permeability, a process that allows inflammatory cells, such as monocytes, neutrophils, and lymphocytes to cross the blood-brain barrier into the central nervous system (74, 76, 77).

More recently shown in the anti-inflammatory mechanism of ketamine is the inhibition of high mobility group box 1 (HMGB1) induced activation of endothelial cells (78, 79). High mobility group box 1 is considered as the main prototype of the emerging injury-associated molecular proteins and indicator of host tissue damage (80, 81). The proinflammatory cytokine is released from endothelial cells, as well as leukocyte adhesion and transmigration, thus, elevated high mobility group box 1 levels could predict non-survivors in subarachnoid hemorrhage, which may be countered by improving neuroinflammation in subarachnoid hemorrhage (82, 83). Ketamine was shown to have an excessive inhibitory effect on high mobility group box 1-induced endothelial cell activation by a mechanism involving nuclear factor κB and toll-like receptor (79, 82, 84).
Conclusion

Much research has been conducted on ketamine’s mechanisms of action; specifically those related to its anti-depressive effects, anti-inflammatory effects, and chronic pain management and cognitive function. For testing long-term efficacy and safety of ketamine in non-anesthetic clinical practice for managing major resistant depression, enhancing memory function in Alzheimer’s patients, and reducing the brain damage after stroke needed for further studies. This review provides evidence of the medical benefits of the non-anesthetic effects of ketamine, as well as supporting evidence of the effectiveness and tolerability of ketamine for managing chronic pain conditions.
References

AKT  Alpha serine/threonine-protein kinase
AMPA  A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
BDNF  Brain-derived neurotrophic factor
eEF2K  Eukaryotic elongation factor-2 kinase
eEF2  Eukaryotic elongation factor-2
ERK  Extracellular signal-regulated kinases
GABA  Gamma-aminobutyric acid
GSK  Glycogen synthase kinase
HNK  Hydroxynorketamine
mTOR  Mammalian target of rapamycin
NMDA  N-methyl-D-aspartate
p-eEF2  Phosphorylated Eukaryotic elongation factor-2
TrKB  Tropomyosin receptor kinase B

Figure 1. Modified and revised from; Vutskits L. General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms. Anesthesia & Analgesia. 2018 Jan 1; 126(1):208-16.